Castle Biosciences Inc., of Friendswood, Texas, said it has begun a proposed underwritten public offering of 1.5 million shares, with the underwriters receiving a 30-day option to purchase up to an additional 225,000 shares at the public offering price. SVB Leerink and Baird are acting as joint book-running managers for the proposed offering and as representatives of the underwriters.

Catalyst Biosciences Inc., of South San Francisco, said it closed an underwritten public offering of 4.61 million shares at $6.50 each for gross proceeds of approximately $30 million. The net proceeds will be used for general corporate purposes.

Greenwich Lifesciences Inc., of Stafford, Texas, has established terms for its IPO and plans to raise up to $21 million by offering 2.7 million shares at a price range of $7.50 to $8.50. The company is developing GP2, an immunotherapy designed to prevent the recurrence of breast cancer following surgery. It is a 9 amino acid transmembrane peptide of the HER2/neu, a cell surface receptor protein that is expressed in 75% of breast cancer in addition to a variety of other common cancers. The company is planning to begin a phase III trial of GP2 this year. It plans to list its shares on Nasdaq under the symbol GLSI.

Iveric Bio Inc., of New York, said it closed its underwritten public offering of 28.5 million shares of its common stock at $4.10 each and, to certain investors in lieu of common stock, prefunded warrants to purchase 1.91 million shares at $4.099 per prefunded warrant. In addition, the company closed its concurrent private placement of 8.64 million shares to affiliates of Vivo Capital LLC and Samsara Biocapital LP, at the public offering price. The net proceeds were approximately $116.9 million from the public offering and approximately $33.1 million from the concurrent private placement.

Leap Therapeutics Inc., of Cambridge, Mass., said it closed a public offering of 20.25 million shares of common stock and prefunded warrants to purchase up to 2.25 million shares of its common stock. The gross proceeds were approximately $45 million.

Outlook Therapeutics Inc., of Monmouth Junction, N.J., said it entered definitive agreements with several health care-focused institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 8.4 million shares at $1.215 each, for aggregate gross proceeds of approximately $10.2 million. In addition, the company has entered a definitive agreement with Syntone Ventures LLC for the purchase and sale, in a private placement priced at-the-market under Nasdaq rules, of 823,045 shares of its common stock at $1.215 each, for aggregate gross proceeds of approximately $1 million. The company intends to use the net proceeds for working capital and general corporate purposes.

Sana Biotechnology Inc., of Seattle, which is focused on engineering cells as medicines for patients, said the funding of all tranches of its initial financing have been completed, raising more than $700 million. The proceeds will be used to advance discovery and development within the company's core platforms, including gene delivery, immunology, stem cell biology, and gene modification and control. They will also support IND-enabling and initial clinical studies for multiple therapeutic candidates, buildout of manufacturing capabilities, and expansion of the company's portfolio of enabling technologies.

Saniona AB, of Copenhagen, which is focused on rare diseases, said it has raised SEK22 million (US$2.3 million) through the sale of 754,577 shares in Scandion Oncology A/S, also of Copenhagen. The sale brings Saniona’s ownership stake in Scandion Oncology below 15%. Proceeds will be used to continue the company’s advancement of mid- and late-stage clinical trials with Tesomet in two rare eating disorders: hypothalamic obesity and Prader-Willi syndrome, as well as to build its U.S.-based leadership team in support of those programs.

Silence Therapeutics plc, of London, said it has confidentially submitted a registration statement to the SEC in connection with a proposed listing of American depositary shares representing the company's ordinary shares on Nasdaq.

Tara Biosystems Inc., of New York, said it completed a $10 million series A2 financing. This financing will be used to scale the company’s cardiac tissue engineering platform technology and advance its drug discovery programs.

No Comments